CONSULTANT PHARMACIST最新文献

Bylines. 署名。

CONSULTANT PHARMACIST Pub Date : 2020-09-25 DOI: 10.2307/j.ctv1d37dq5.5

H. Davidson

引用次数: 0

Management of Primary Sjögren's Syndrome. 原发性Sjögren综合征的治疗。

CONSULTANT PHARMACIST Pub Date : 2018-12-01 DOI: 10.4140/TCP.n.2018.691.

Leisa L Marshall, Gregg A Stevens

{"title":"Management of Primary Sjögren's Syndrome.","authors":"Leisa L Marshall, Gregg A Stevens","doi":"10.4140/TCP.n.2018.691.","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.691.","url":null,"abstract":"OBJECTIVE: Review the clinical manifestations and treatment of primary Sjögren's syndrome. DATA SOURCES: Articles indexed in PubMed, Scopus, and the Cochrane Library in the past 10 years using the key words \"Sjögren,\" \"Sjögren's syndrome,\" \"Sjögren's disease,\" and \"Sjögren's syndrome AND treatment.\" Primary sources were used to locate additional resources. STUDY SELECTION AND DATA EXTRACTION: Forty-six publications were reviewed and criteria supporting the primary objective were used to identify useful resources. DATA SYNTHESIS: The literature included practice guidelines, review articles, original research articles, and prescribing information for the manifestations, diagnosis, and treatment of primary Sjögren's syndrome. CONCLUSION: Primary Sjögren's syndrome is a chronic autoimmune disease with various clinical manifestations, notably dry eye, dry mouth, fatigue, and inflammatory musculoskeletal pain. Most patients are under the care of a dentist, ophthalmologist, and rheumatologist. There is currently no cure; therapy is tailored for each patient to reduce symptoms, avoid complications, and improve quality of life. Respondents to a recent survey conducted by the Sjögren's Syndrome Foundation reported using more than eight medications and treatments for their symptoms; more than 60% of respondents were older than 60 years of age. Pharmacists familiar with recommended treatment options can provide advice and counseling to Sjögren's syndrome patients on multi-drug regimens prescribed by different health care practitioners.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36822253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam. 临床药师干预老年人减少阿普唑仑的使用。

CONSULTANT PHARMACIST Pub Date : 2018-12-01 DOI: 10.4140/TCP.n.2018.711.

Hilary J Navy, Linda Weffald, Thomas Delate, Rachana J Patel, Jennifer P Dugan

{"title":"Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam.","authors":"Hilary J Navy, Linda Weffald, Thomas Delate, Rachana J Patel, Jennifer P Dugan","doi":"10.4140/TCP.n.2018.711.","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.711.","url":null,"abstract":"OBJECTIVE: To assess whether a letter explaining the risks of alprazolam can engage older adults to call a clinical pharmacist (CP) to initiate reduction in alprazolam use. DESIGN: Randomized, controlled study. SETTING: Integrated health care delivery system. PATIENTS: Patients 65 years of age and older who resided at home, had a current supply of alprazolam as of December 15, 2016, and had four outpatient dispensings of alprazolam during the previous 12 months. INTERVENTION: Patients were randomized to receive an educational outreach regarding alprazolam use reduction via a mailed letter (intervention group) or receive usual care (control group). Intervention patients/caregivers were requested to call the CP to discuss reduction of alprazolam use. For intervention patients who called and consented to participate, alternative treatment options were discussed on a case-by-case basis. MAIN OUTCOME MEASURES: Composite rate of 1) no alprazolam dispensing, 2) an alprazolam dose reduction, or 3) interchange to an alternative medication during the six-month follow-up. RESULTS: 153 and 173 patients were and were not, respectively, sent a letter. The mean age was 73 years and patients primarily were female. Thirty (19.6%) intervention patients called the CP. The composite rate was equivalent between the intervention (34.0%) and control (35.3%) groups (P = 0.822). In subanalyses, the composite rate was higher among intervention patients who did vs. those who did not call the CP (77.8% vs. 27.6%; P < 0.001). CONCLUSION: A low-cost patient educational outreach coupled with CP care efficiently engaged older adults in benzodiazepine use reduction process; however, alprazolam continues to be a challenging medication for patients to discontinue.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36780112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Digging Deeper Into the Patient-Driven Payment Model. 深入挖掘病人驱动的支付模式。

CONSULTANT PHARMACIST Pub Date : 2018-12-01 DOI: 10.4140/TCP.n.2018.724.

Paul Baldwin

引用次数: 0

ASCP's Peer-Review Journal is Getting a Makeover. ASCP的同行评议期刊正在改头换面。

CONSULTANT PHARMACIST Pub Date : 2018-12-01

Chad Worz

引用次数: 0

Identifying Cognitive Impairment in an Older Adult Using Two Different Screening Tools. 使用两种不同的筛查工具识别老年人的认知障碍。

CONSULTANT PHARMACIST Pub Date : 2018-12-01 DOI: 10.4140/TCP.n.2018.702.

Anushka Tandon, Sunny A Linnebur, Maria V Vejar

引用次数: 0

"I Have a Voice, Too". “我也有声音”。

CONSULTANT PHARMACIST Pub Date : 2018-12-01

H Edward Davidson

引用次数: 0

Increased Use of Medical Marijuana: Skepticism vs. Evidence. 医用大麻使用的增加:怀疑与证据。

CONSULTANT PHARMACIST Pub Date : 2018-12-01 DOI: 10.4140/TCP.n.2018.680.

Jeannette Y Wick

{"title":"Increased Use of Medical Marijuana: Skepticism vs. Evidence.","authors":"Jeannette Y Wick","doi":"10.4140/TCP.n.2018.680.","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.680.","url":null,"abstract":"The use of medical marijuana-both the psychoactive tetrahydrocannabinol and its nonpsychoactive relative cannabidiol-is a growing practice in facilities served by senior care pharmacists. Currently, 30 states have approved its use under a variety of different regulations and for a number of conditions. Its use is bolstered by a growing number of Americans who support legalization of cannabis. Though oral synthetic cannabinoid compounds are approved by the Food and Drug Administration for chemotherapy-induced nausea and vomiting and appetite stimulation associated with AIDS, synthetic products differ from plant-derived products in several ways. In addition, use of these substances has created a regulatory and legal quagmire that differs considerably depending on the state in which the pharmacist practices. In long-term care, pharmacists face an entirely different set of challenges than pharmacists who practice in other settings: Increasingly, long-term care residents and their attending physicians are asking to use medical marijuana. This manuscript discusses how some long-term care facilities are accommodating this substance that federally and in many states is considered illegal. It also discusses some of the challenges faced by pharmacists who work in dispensaries.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36822252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statins: The Burglar of Memory? 他汀类药物:记忆窃贼?

CONSULTANT PHARMACIST Pub Date : 2018-12-01 DOI: 10.4140/TCP.n.2018.706.

Tara Nicole Downs

{"title":"Statins: The Burglar of Memory?","authors":"Tara Nicole Downs","doi":"10.4140/TCP.n.2018.706.","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.706.","url":null,"abstract":"Alzheimer's disease is becoming more predominant in our aging population. Statin medications have been reported to contribute to cognitive impairment. Updated cholesterol treatment guidelines significantly increase the proportion of people eligible for treatment with statins. Therefore, uncommon adverse effects related to this medication class have the potential to impact health care by increasing cognitive impairment and/or contributing to statin treatment avoidance. CASE: An 83-year-old Caucasian male was seen in a cognitive evaluation clinic for noticeable memory decline. Memory impairment was confirmed using validated cognitive assessments. Atorvastatin was identified as a possible cause of memory impairment. Shared-decision making between the patient and interdisciplinary team was utilized to discontinue atorvastatin to determine causation. Over a period of 18 months, the patient's cognitive scores initially improved after statin medication was discontinued. However, over time, cognitive scores returned to baseline for memory decline without restart or retrial of any statin within the class. DISCUSSION: This case report is consistent with many previous studies that fail to find an association between statins and cognitive impairment. The course of this case is unique in that the likelihood of association of cognitive impairment decreases with time, highlighting the importance of extended follow-up care. It also highlights the importance of evaluating the evidence supporting the Food and Drug Administration's drugsafety communications to ameliorate any concerns regarding medication therapy, in this case statin therapy. CONCLUSION: This case report is consistent with recent literature that fails to demonstrate an association between statins and cognitive impairment. It also provides support for the practitioner to prescribe and continue statins without fear of precipitating or worsening cognitive impairment.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36780111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Management of Non-Cystic Fibrosis Bronchiectasis. 非囊性纤维化支气管扩张症的治疗。

CONSULTANT PHARMACIST Pub Date : 2018-11-01 DOI: 10.4140/TCP.n.2018.658.

Stacey K Dull, Brooke D Havlat, Michael J Sanley, Mark A Malesker

引用次数: 0